In a further analysis of the prognostic value of the cellular subpopulation of CTCs, we found that CRC patients with high expression of CD133+CD54+ (P < 0.001), CD133−CD54+ (P = 0.004), and CD133+CD44+CD54+ (P = 0.003) subpopulations of CTCs had a worse survival than those with low expression. This evidence concerns the gene CD44 and colorectal carcinoma.